Acquisitions (Tables)

9 Months Ended

Sep. 30, 2013

Incline Therapeutics, Inc. [Member]

Business Acquisition [Line Items]

Schedule of Estimated Purchase Price

Total estimated purchase price is summarized as follows:

	(in thousands)
Upfront cash consideration	$	186,699
Fair value of contingent purchase price	87,200
Total preliminary estimated purchase price	$	273,899

Schedule of Recognized Identified Assets Acquired and Liabilities Assumed

Below is a summary which details the preliminary allocation of assets acquired and liabilities assumed as a result of this acquisition:

Assets Acquired:	(in thousands)
Cash and cash equivalents	$	1,563
Prepaid expenses and other current assets	624
Fixed assets, net	12,577
In-process research and development	250,000
Goodwill	99,956
Other assets	34
Total Assets	$	364,754
Liabilities Assumed:
Accrued expenses	$	1,413
Contingent purchase price	87,200
Deferred tax liabilities	89,442
Total Liabilities	$	178,055
Total cash price paid upon acquisition	$	186,699

Bristol-Myers Squibb [Member]

Business Acquisition [Line Items]

Schedule of Recognized Identified Assets Acquired and Liabilities Assumed

Below is a summary which details the preliminary allocation of assets acquired as a result of this acquisition:

Assets Acquired:	(in thousands)
Product license	$	32,000
Option	62,000
Goodwill	21,000
Total Assets	$	115,000
Total cash price paid upon acquisition	$	115,000

ProFibrix [Member]

Business Acquisition [Line Items]

Schedule of Estimated Purchase Price

Total estimated purchase price is summarized as follows:

	(in thousands)
Upfront cash consideration	$	100,879
Fair value of contingent purchase price	82,550
Total preliminary estimated purchase price	$	183,429

Schedule of Recognized Identified Assets Acquired and Liabilities Assumed

Below is a summary which details the preliminary allocation of assets acquired and liabilities assumed as a result of this acquisition:

Assets Acquired:	(in thousands)
Fixed assets, net	$	124
In-process research and development	176,000
Goodwill	51,311
Total Assets	$	227,435
Liabilities Assumed:
Contingent purchase price	$	82,550
Deferred tax liabilities	44,006
Total Liabilities	$	126,556
Total cash price paid upon acquisition	$	100,879

Business Acquisition, Pro Forma Information

The pro forma financial information is not necessarily indicative of the results of operations as they would have been had the transaction been effected on the assumed date.

	Three Months Ended September 30,					Nine Months Ended September 30,
	2013		2012			2013		2012
	(in thousands, except per share amounts)
Net revenue	$	174,282	$	153,398		$	509,214	$	448,934
Net (loss) income	$	4,739	$	(403	)	$	5,569	$	(73,131	)
Basic earnings (loss) per common share	$	0.08	$	(0.01	)	$	0.10	$	(1.36	)
Diluted earnings (loss) per common share	$	0.08	$	(0.01	)	$	0.09	$	(1.36	)